[Results of chemoimmune prophylaxis of superficial bladder carcinoma (author's transl)].
41 patients with superficial urothelial bladder cancer were subjected to chemoimmune prophylaxis with i.v. cyclophosphamide and intravesical as well as systemic BCG treatment, after complete tumor resection. Compared with a historical patient control group treated by tumor resection alone, the chemoimmune treatment group exhibited a distinct reduction of the recurrence rate. This difference was most marked during the first 6 months postoperatively. The side effects of this treatment were tolerable. Our results are discussed with regard to the reported findings in the literature. Possible immune biological mechanisms of the tumor protection achieved by cyclophosphamide/BCG are suggested.
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy
D001500:BCG Vaccine; D003520:Cyclophosphamide
Ergebnisse der Chemoimmunprophylaxe bei oberflächlichen Harnblasenkarzinomen.